ARTICLE | Company News
Vigene gains rights to Virovek's AAV production tech
April 20, 2018 7:07 PM UTC
Viral vector production company Vigene Biosciences Inc. (Rockville, Md.) gained exclusive, worldwide rights to adeno-associated virus (AAV) production technology, BAC-to-AAV, from Virovek Inc. (Hayward, Calif.).
Under the deal, Virovek will waive license fees for Phase I, II and III trials plus associated milestones for gene therapy developers that use AAVs produced by Vigene via BAC-to-AAV technology. Vigene declined to disclose financial terms...